Novartis Ag (NVS) Operating Leases (2019 - 2026)

Novartis Ag's Operating Leases history runs 8 years deep, the most recent figure standing at $271.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 11.98% year-over-year to $271.0 million; the TTM figure through Mar 2026 stood at $271.0 million (up 11.98% YoY), while the FY2025 annual figure was $263.0 million, up 11.91% from the prior year.
• Operating Leases came in at $271.0 million for Q1 2026 at Novartis Ag, up from $263.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.6 billion in Q2 2025 to a low of -$12.0 million in Q1 2022.
• A 5-year average of $521.4 million and a median of $248.0 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 104.3% in 2022 and surged 2191.67% in 2023, its largest moves.
• Novartis Ag's Operating Leases stood at $23.0 million in 2022, then surged by 534.78% to $146.0 million in 2023, then jumped by 60.96% to $235.0 million in 2024, then grew by 11.91% to $263.0 million in 2025, then advanced by 3.04% to $271.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $271.0 million, $263.0 million, and $264.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison